Phosphatidylcholine for Steroid-Refractory Chronic Ulcerative Colitis

A Randomized Trial

  1. Wolfgang Stremmel, MD;
  2. Robert Ehehalt, MD;
  3. Frank Autschbach, MD; and
  4. Max Karner, MD
  1. From University Hospital Heidelberg, Heidelberg, Germany.

    Abstract

    Background: Although long-term steroid treatment is discouraged in ulcerative colitis, alternatives are lacking when therapy with immunosuppressant drugs fails. An insufficient level of phosphatidylcholine in colonic mucus is a possible pathogenetic factor for ulcerative colitis.

    Objective: To see whether steroid withdrawal is easier with retarded-release phosphatidylcholine or placebo in adults with chronic steroid-refractory ulcerative colitis.

    Design: Randomized, double-blind, placebo-controlled trial conducted from March 2003 to January 2006.

    Setting: University Hospital Heidelberg, a referral center for inflammatory bowel disease.

    Patients: 60 patients with chronic steroid-refractory ulcerative colitis and high clinical and endoscopic disease activity indexes (score ≥5).

    Intervention: Phosphatidylcholine or cellulose placebo was ingested 4 times daily for 12 weeks for a total dosage of 2 g/d. The follow-up rate was 97%.

    Measurements: The number of patients achieving complete steroid withdrawal and either a low clinical activity index (≤3) or improvement in the clinical activity index of 50% or more.

    Results: The primary end point was achieved in 15 of 30 (50%) phosphatidylcholine recipients and in 3 of 30 (10%) placebo recipients (difference, 40% [95% CI, 19% to 61%]; P = 0.002). Twenty-four phosphatidylcholine recipients (80%) and 3 (10%) placebo recipients discontinued steroid therapy without disease exacerbation (difference, 70% [CI, 52% to 88%]; P <0.001). Mild bloating was a common adverse event.

    Limitations: The sample size was small, and the study was of short duration.

    Conclusion: Phosphatidylcholine reduced corticosteroid dependence more than placebo in patients with chronic steroid-refractory ulcerative colitis. The next step is long-term trials to evaluate the sustainability of steroid withdrawal in these patients.

    ClinicalTrials.gov registration number: NCT00259545.

    Article and Author Information

    • Acknowledgment: The authors thank Susanne Schäfer for statistical analysis; Annika Braun, MD, and Alexandra Zahn, MD, for assistance in patient management; and Heather Karner, MA, for proofreading and editing services. They also thank Verena Schmieg and Anja Hanemann for assistance in assessing the follow-up data and Daniela Kautz and Anja Hanemann for assisting in the data management and graph generation.

    • Grant Support: By the Dietmar-Hopp Foundation (Dr. Stremmel).

    • Potential Financial Conflicts of Interest: Grants received: W. Stremmel (Dietmar-Hopp Foundation). Patents received: W. Stremmel (for retarded-release phosphatidylcholine as a mucoprotective agent for the large intestine.)

    • Reproducible Research Statement: The protocol (in German, with an English-language synopsis), data set, and statistical code are available to interested readers by contacting Dr. Stremmel (e-mail, wolfgang.stremmel{at}med.uni-heidelberg.de).

    • Requests for Single Reprints: Wolfgang Stremmel, MD, Department of Gastroenterology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany; e-mail, wolfgang.stremmel{at}med.uni-heidelberg.de.

    • Current Author Addresses: Drs. Stremmel, Ehehalt, and Karner: Department of Gastroenterology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.

    • Dr. Autschbach: Pathological Institute, University Hospital Heidelberg, Im Neuenheimer Feld 220/221, 69120 Heidelberg, Germany.

    • Author Contributions: Conception and design: W. Stremmel, M. Karner.

    • Analysis and interpretation of the data: W. Stremmel, R. Ehehalt, M. Karner.

    • Drafting of the article: W. Stremmel, M. Karner.

    • Critical revision of the article for important intellectual content: W. Stremmel, M. Karner.

    • Final approval of the article: W. Stremmel, R. Ehehalt, F. Autschbach, M. Karner.

    • Provision of study materials or patients: W. Stremmel, F. Autschbach, M. Karner.

    • Statistical expertise: W. Stremmel, M. Karner.

    • Obtaining of funding: W. Stremmel.

    • Administrative, technical, or logistic support: W. Stremmel, R. Ehehalt, M. Karner.

    • Collection and assembly of data: W. Stremmel, R. Ehehalt, F. Autschbach, M. Karner.

    « Previous | Next Article »Table of Contents